Indivior Pharmaceuticals (INDV) Common Equity (2021 - 2026)

Indivior Pharmaceuticals' Common Equity history runs 6 years deep, the most recent figure standing at -$144.0 million for Q1 2026.

• In Q1 2026, Common Equity rose 49.47% year-over-year to -$144.0 million; the TTM figure through Mar 2026 stood at -$144.0 million (up 49.47% YoY), while the FY2025 annual figure was -$98.0 million, up 70.92% from the prior year.
• Common Equity was -$144.0 million for Q1 2026 at Indivior Pharmaceuticals, down from -$98.0 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of -$15.0 million in Q4 2022 to a low of -$337.0 million in Q4 2024.
• Historically, Common Equity has averaged -$207.2 million across 5 years, with a median of -$207.0 million in 2025.
• The sharpest annual moves came in 2023 and 2025: Common Equity slumped 1126.67% in 2023, then surged 70.92% in 2025.
• A 5-year view of Common Equity shows it stood at -$15.0 million in 2022, then plunged by 1126.67% to -$184.0 million in 2023, then tumbled by 83.15% to -$337.0 million in 2024, then soared by 70.92% to -$98.0 million in 2025, then slumped by 46.94% to -$144.0 million in 2026.
• The last three Common Equity figures came in at -$144.0 million (Q1 2026), -$98.0 million (Q4 2025), and -$207.0 million (Q3 2025), per Business Quant data.